A Prospective, Randomized, Clinical Trial to Compare Adverse Birth Outcomes in Pregnant Women Receiving Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4)
Latest Information Update: 29 Dec 2022
At a glance
- Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; GSK 1536489A
- Indications Influenza virus infections
- Focus Adverse reactions
Most Recent Events
- 27 Oct 2021 Status changed from active, no longer recruiting to completed.
- 05 Apr 2021 Planned End Date changed from 14 Sep 2022 to 14 Sep 2021.
- 01 Apr 2021 Status changed from recruiting to active, no longer recruiting.